Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an archived version available post-event.

Fate Therapeutics reported its first quarter 2024 financial results and business updates, highlighting progress in clinical areas, including treating the first lupus patient with FT819 CAR T-cell therapy, initiating enrollment for FT522 CAR NK cell therapy, and treating the first patient with FT825 CAR T-cell therapy. The company has $391 million in cash, cash equivalents, and investments. The financial results include $1.9 million in revenue, $53.0 million in operating expenses, and total outstanding shares of 113.8 million.

Fate Therapeutics announced the treatment of the first lupus patient in the Phase 1 autoimmunity study of FT819 CAR T-cell program. The patient showed rapid and potent depletion of CD19+ B cells. The company also presented translational data from the Phase 1 study of FT819 in B-cell malignancies and initial clinical observations from the FT522 CAR NK cell program in B-cell lymphoma. These programs highlight key therapeutic mechanisms for autoimmune diseases.

Fate Therapeutics, Inc. will report its first quarter 2024 financial results and operational updates during a conference call on May 9, 2024. The company focuses on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, with programs like FT819 and FT522. The event coincides with the American Society of Gene and Cell Therapy 27th Annual Meeting.

Fate Therapeutics announced preclinical data for its FT522 program for autoimmune diseases at the ASGCT Annual Meeting. FT522, a CD19-targeted CAR NK cell product candidate, showed promising results in depleting SLE donor B cells and eliminating host immune cells. The ADR technology incorporated into FT522 enhances its potency, potentially offering a new treatment approach for autoimmune diseases.

Fate Therapeutics announces presentation of FT819 proof-of-concept data for B cell-mediated autoimmune diseases at ASGCT Annual Meeting. The data highlights key therapeutic mechanisms of clinical activity, including B cell depletion, tissue infiltration, and immune reconstitution, from Phase 1 study of FT819 in relapsed/refractory B-cell malignancies. The company also initiated patient enrollment in a Phase 1 study of FT819 off-the-shelf, CD19-targeted, iPSC-derived CAR T-cell therapy for systemic lupus erythematosus.

Fate Therapeutics, Inc. (NASDAQ: FATE) will present at the 23rd Annual Needham Virtual Healthcare Conference to discuss their iPSC-derived cellular immunotherapies for cancer and autoimmune disorders. The webcast will be available on the company's website for viewing after the event.

Fate Therapeutics (FATE) granted 6,400 restricted stock units to a new non-executive employee. The RSUs will vest over four years, subject to continuous employment. The grant was approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

Fate Therapeutics, Inc. announces the pricing of an underwritten offering of 14,545,454 shares of its common stock at $5.50 per share, along with a concurrent private placement of pre-funded warrants. The Company expects gross proceeds of approximately $100.0 million from the offerings, with participation from various institutional investors.